Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SELLAS Life Sciences Group, Inc. - Common Stock (NQ:SLS)

4.930 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 36,807
Open 4.930
Bid (Size) 4.960 (1,500)
Ask (Size) 5.000 (2,100)
Prev. Close 4.930
Today's Range 4.930 - 4.930
52wk Range 1.260 - 6.140
Shares Outstanding 15,873,941
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum ↗
Investors are also watching the late-stage GPS immunotherapy trial, which is nearing final analysis with 72 of 80 survival events recorded. 
Via Stocktwits
News headline image
SLS Stock In Spotlight: First AML Patient Enrolled In Phase 2 Leukemia Trial ↗
The study aims to evaluate SLS009’s effectiveness in a molecularly defined cohort of frontline leukemia patients, enrolling approximately 80 patients across two high-priority groups. 
Via Stocktwits

Performance

YTD
+13.3%
+13.3%
1 Month
-2.2%
-2.2%
3 Month
+28.4%
+28.4%
6 Month
+128.2%
+128.2%
1 Year
+285.2%
+285.2%

More News

Read More
News headline image
SLS Stock Rallies Ahead Of AML Trial Readout — ‘Pharma Bro’ Martin Shkreli Says He’s Still ‘Very Bearish,’ Predicts Drug Will Fail ↗
Via Stocktwits
News headline image
Dow, S&P 500, Nasdaq Futures Dip After Wall Street Rebound: Why SLS, ZVRA, RLMD, USO, CASY Are Trending After-Hours ↗
Via Stocktwits
Topics ETFs Government Stocks
SELLAS Life Sciences Falls For Fourth Straight Session — What’s Driving The Sell Off? ↗
Via Stocktwits
News headline image
SLS Stock Falls Premarket: CEO Touts GPS Leukemia Strategy, But Investors Stay Cautious As AML Trial Nears Readout ↗
Via Stocktwits
News headline image
SLS Stock Takes A Breather After Big Run: Traders Eye AML Summit Featuring Advisor For Clues On Trial Readout ↗
Via Stocktwits
News headline image
SLS Stock’s Red-Hot Streak Draws Rising Short Bets — Retail Traders Are Now Betting On A Big Pharma Buyout ↗
Via Stocktwits
News headline image
SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside ↗
Via Stocktwits
News headline image
SLS Stokes Retail Anticipation For Breakout Rally — What’s Driving The Interest? ↗
Via Stocktwits
Topics Death
News headline image
Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% ↗
Via Stocktwits
Topics Regulatory Compliance
News headline image
SLS Stock In Spotlight On EU Expansion For Cancer Therapy – Retail Says Potential Catalyst For Buyout ↗
Via Stocktwits
News headline image
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
From Equity Insider
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session. ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Edge Lower Despite CES-Driven AI Optimism: Why NVDA, TSLA, AMD, AEVA, OS Are On Traders' Radar Today ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Stocks
News headline image
SLS Stock Breaches $5 Level After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B ↗
Via Stocktwits
Topics Death
News headline image
Why Is SLS Stock Drawing Significant Investor Attention Today? ↗
Via Stocktwits
Topics Death
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
SELLAS Life Sciences Group Stock Soars As It Nears Final Analysis In Cancer Study ↗
Via Stocktwits
Topics Death
News headline image
SLS Stock Has Risen 78% In A Month — What’s The Retail Buzz About? ↗
Via Stocktwits
News headline image
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
From Equity Insider
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
SELLAS Life Sciences Stock Has Doubled This Year – Here’s Why Retail Investors Are Bullish ↗
Via Stocktwits
Topics Death
News headline image
SELLAS Life Sciences Draws Retail Buzz On SLS009 Trial Momentum – Stock Soars In Pre-Market ↗
Via Stocktwits
Topics Artificial Intelligence

Frequently Asked Questions

Is SELLAS Life Sciences Group, Inc. - Common Stock publicly traded?
Yes, SELLAS Life Sciences Group, Inc. - Common Stock is publicly traded.
What exchange does SELLAS Life Sciences Group, Inc. - Common Stock trade on?
SELLAS Life Sciences Group, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for SELLAS Life Sciences Group, Inc. - Common Stock?
The ticker symbol for SELLAS Life Sciences Group, Inc. - Common Stock is SLS on the Nasdaq Stock Market
What is the current price of SELLAS Life Sciences Group, Inc. - Common Stock?
The current price of SELLAS Life Sciences Group, Inc. - Common Stock is 4.930
When was SELLAS Life Sciences Group, Inc. - Common Stock last traded?
The last trade of SELLAS Life Sciences Group, Inc. - Common Stock was at 04/16/26 04:00 PM ET
What is the market capitalization of SELLAS Life Sciences Group, Inc. - Common Stock?
The market capitalization of SELLAS Life Sciences Group, Inc. - Common Stock is 78.26M
How many shares of SELLAS Life Sciences Group, Inc. - Common Stock are outstanding?
SELLAS Life Sciences Group, Inc. - Common Stock has 78M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.